Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

GARON, Edward; CİULEANU, Tudor-Eliade; ARRİETA, Oscar; PRABHASH, Kumar; SYRIGOS, Konstantinos; GÖKSEL, TUNCAY; PARK, Keunchil; GORBUNOVA, Vera; DARIO KOWALYSZYN, Ruben; PİKİEL, Joanna; CZYZEWICZ, Grzegorz; ORLOV, Sergey; LEWANSKI, Conrad; THOMAS, Michael; BIDOLI, Paolo; DAKHIL, Shaker; GANS, Steven; KIM, Joo-Hang; GRIGORESCU, Alexandru; KARASEVA, Nina; RECK, Martin; CAPPUZZO, Federico; ALEXANDRİS, Ekaterine; SASHEGYI, Andreas; YURASOV, Sergey; PEROL, Maurice

doi:10.1016/s0140-6736(14)60845-x

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

Atıf İçin Kopyala

GARON E. B. , CİULEANU T., ARRİETA O., PRABHASH K., SYRIGOS K. N. , GÖKSEL T. , ...Daha Fazla

LANCET, cilt.384, ss.665-673, 2014 (SCI İndekslerine Giren Dergi)

Cilt numarası: 384 Konu: 9944
Basım Tarihi: 2014
Doi Numarası: 10.1016/s0140-6736(14)60845-x
Dergi Adı: LANCET
Sayfa Sayıları: ss.665-673

Özet

Background Ramucirumab is a human IgG1 monoclonal antibody that targets the extracellular domain of VEGFR-2. We aimed to assess efficacy and safety of treatment with docetaxel plus ramucirumab or placebo as second-line treatment for patients with stage IV non-small-cell-lung cancer (NSCLC) after platinum-based therapy.